For the Inventor, By the Inventor

Enter assignee name

Manchester, United Kingdom

Oxyrane UK Limited

USPTO Granted Patents = 16

CIPO Patents = 3

EPO Patents = 9

Forward Citations = 103

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Wouter Vervecken (16 out of 18 patents)

Kathleen Camilla Telesphore Alida Maria Piens (8 out of 8 patents)

Steven Christian Jozef Geysens (7 out of 7 patents)

4. Nico Luc Marc Callewaert (7 out of 7 patents)

5. Karen Jacqueline Marcel De Pourcq (5 out of 5 patents)

6. Mouna Guerfal (5 out of 5 patents)

7. Gwenda Noëlla Pynaert (4 out of 4 patents)

8. Jan Robert Ludo Stout (2 out of 2 patents)

9. Han Karel Remaut (2 out of 10 patents)

10. Albena Vergilieva Valevska (2 out of 2 patents)

11. Petra Sophie Tiels (2 out of 3 patents)

12. Steven Geysens (1 out of 4 patents)

13. Stefan Simonne Prudent Eugène Christine Ryckaert (0 patent)

14. Kathleen Camilla Piens (0 patent)

15. Nico Luc Callewaert (0 patent)

16 patents: Sort by Forward Citations

1. 11225646 - Yeast strains producing mammalian-like complex n-glycans (2022-01-18),

2. 11040114 - Human alpha-N-acetylgalactosaminidase polypeptide (2021-06-22),

3. 10648044 - Methods and materials for treatment of Pompe's disease (2020-05-12),

4. 10392609 - Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose (2019-08-27),

5. 10344310 - De-mannosylation of phosphorylated N-glycans (2019-07-09),

6. 10287557 - Yeast strains producing mammalian-like complex N-glycans (2019-05-14),

7. 10023854 - Microorganisms genetically engineered to have modified N-glycosylation activity (2018-07-17),

8. 10011857 - Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins (2018-07-03),

9. 9689015 - De-mannosylation of phosphorylated N-glycans (2017-06-27),

10. 9598682 - Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose (2017-03-21),

11. 9347050 - Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins (2016-05-24),

12. 9249399 - Methods and materials for treatment of pompe's disease (2016-02-02),

13. 9222083 - Microorganisms genetically engineered to have modified N-glycosylation activity (2015-12-29),

14. 9206408 - Microorganisms genetically engineered to have modified N-glycosylation activity (2015-12-08),

15. 8597906 - Glycosylation of molecules (2013-12-03),

Oxyrane UK Limited is a biotechnology company specialized in the development of novel enzyme replacement therapies (ERTs) for rare genetic diseases. With a mission to improve the lives of patients and their families, Oxyrane focuses on the research, development, and commercialization of advanced therapies to address unmet medical needs. Combining cutting-edge science with deep expertise, Oxyrane aims to provide innovative treatments that can significantly impact the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

16 Patents

#18 in Manchester

#1,100 in United Kingdom

#36,654 in the World

Manchester, United Kingdom

Oxyrane UK Limited

Forward Citations = 103

12 inventors:

Wouter Vervecken (16 out of 18 patents)

Kathleen Camilla Telesphore Alida Maria Piens (8 out of 8 patents)

Steven Christian Jozef Geysens (7 out of 7 patents)

4. Nico Luc Marc Callewaert (7 out of 7 patents)

5. Karen Jacqueline Marcel De Pourcq (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…